Springate D.A., Parisi R., Kontopantelis E., Reeves D., Griffiths C.E., Ashcroft D.M. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017;176(3):650–658. https://doi.org/10.1111/bjd.15021..
DOI: 10.1111/bjd.15021

Gladman D.D., Antoni C., Mease P., Clegg D.O., Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(2 Suppl.):ii14–17. https://doi.org/10.1136/ard.2004.032482..
DOI: 10.1136/ard.2004.032482

Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441–447. https://doi.org/10.2165/00128071-200304070-00001..
DOI: 10.2165/00128071-200304070-00001

Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. https://doi.org/10.1016/S0140-6736(07)61128-3..
DOI: 10.1016/S0140-6736(07)61128-3

Rapp S.R., Feldman S.R., Exum M.L., Fleischer A.B. Jr, Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. https://doi.org/10.1016/s0190-9622(99)70112-x..
DOI: 10.1016/s0190-9622(99)70112-x

Ni C., Chiu M.W. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119–132. https://doi.org/10.2147/CCID.S44843..
DOI: 10.2147/CCID.S44843

Mehta N.N., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–1006. https://doi.org/10.1093/eurheartj/ehp567..
DOI: 10.1093/eurheartj/ehp567

Jindal S., Jindal N. Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship. Cureus. 2018;10(2):e2195. https://doi.org/10.7759/cureus.2195..
DOI: 10.7759/cureus.2195

Fu Y., Lee C.H., Chi C.C. Association of Psoriasis with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(12):1417–1423. https://doi.org/10.1001/jamadermatol.2018.3631..
DOI: 10.1001/jamadermatol.2018.3631

Потекаев Н.Н., Жукова О.В., Артемьева С.И. Псориаз: персонифицированный подход к терапии. Предпочтительный выбор системных агентов с учетом коморбидных патологий. Медицинский совет. 2020;(12):28–34. https://doi.org/10.21518/2079-701X-2020-12-28-34..
DOI: 10.21518/2079-701X-2020-12-28-34

Bhutani T., Patel T., Koo B., Nguyen T., Hong J., Koo J. A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. J Am Acad Dermatol. 2013;69(2):e79–e88. https://doi.org/10.1016/j.jaad.2012.10.009..
DOI: 10.1016/j.jaad.2012.10.009

Gelfand J.M. Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answer. J Am Acad Dermatol. 2018;79(1):69–70. https://doi.org/10.1016/j.jaad.2018.03.046..
DOI: 10.1016/j.jaad.2018.03.046

Wu J.J., Sundaram M., Cloutier M., Gauthier-Loiselle M., Guérin A., Singh R., Ganguli A. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study. J Am Acad Dermatol. 2018;79(1):60–68. https://doi.org/10.1016/j.jaad.2018.02.050..
DOI: 10.1016/j.jaad.2018.02.050

Mehta N.N., Shin D.B., Joshi A.A., Dey A.K., Armstrong A.W., Duffin K.C. et al. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. Circ Cardiovasc Imaging. 2018;11(6):e007394. https://doi.org/10.1161/CIRCIMAGING.117.007394..
DOI: 10.1161/CIRCIMAGING.117.007394

Menter A., Strober B.E., Kaplan D.H., Kivelevitch D., Prater E.F., Stoff B. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. https://doi.org/10.1016/j.jaad.2018.11.057..
DOI: 10.1016/j.jaad.2018.11.057

Hawkes J.E., Yan B.Y., Chan T.C., Krueger J.G. Discovery of the IL-23/ IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6):1605–1613. https://doi.org/10.4049/jimmunol.1800013..
DOI: 10.4049/jimmunol.1800013

Chan T.C., Hawkes J.E., Krueger J.G. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119. https://doi.org/10.1177/2040622318759282..
DOI: 10.1177/2040622318759282

Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. https://doi.org/10.1016/j.jaci.2017.07.004..
DOI: 10.1016/j.jaci.2017.07.004

Fragoulis G.E., Siebert S., McInnes I.B. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases. Annu Rev Med. 2016;67:337–353. https://doi.org/10.1146/annurev-med-051914-021944..
DOI: 10.1146/annurev-med-051914-021944

Piskin G., Sylva-Steenland R.M., Bos J.D., Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176(3):1908–1915. https://doi.org/10.4049/jimmunol.176.3.1908..
DOI: 10.4049/jimmunol.176.3.1908

Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. https://doi.org/10.1084/jem.20030451..
DOI: 10.1084/jem.20030451

Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. https://doi.org/10.1056/NEJMra0804595..
DOI: 10.1056/NEJMra0804595

Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350. https://doi.org/10.1038/jid.2009.59..
DOI: 10.1038/jid.2009.59

Machado Á., Torres T. Guselkumab for the Treatment of Psoriasis. BioDrugs. 2018;32(2):119–128. https://doi.org/10.1007/s40259-018-0265-6..
DOI: 10.1007/s40259-018-0265-6

Yang E.J., Smith M.P., Ly K., Bhutani T. Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. Drug Des Devel Ther. 2019;13:1993–2000. https://doi.org/10.2147/DDDT.S137588..
DOI: 10.2147/DDDT.S137588

Blauvelt A., Papp K., Gottlieb A., Jarell A., Reich K., Maari C. et al. A head-tohead comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358. https://doi.org/10.1111/bjd.18851..
DOI: 10.1111/bjd.18851

Blauvelt A., Papp K.A., Griffiths C.E., Randazzo B., Wasfi Y., Shen Y.K. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. https://doi.org/10.1016/j.jaad.2016.11.041..
DOI: 10.1016/j.jaad.2016.11.041

Reich K., Armstrong A.W., Foley P., Song M., Wasfi Y., Randazzo B. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. https://doi.org/10.1016/j.jaad.2016.11.042..
DOI: 10.1016/j.jaad.2016.11.042

Reich K., Griffiths C.E.M., Gordon K.B., Papp K.A., Song M., Randazzo B. et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–945. https://doi.org/10.1016/j.jaad.2019.11.040..
DOI: 10.1016/j.jaad.2019.11.040

Reich K., Armstrong A.W., Foley P., Song M., Miller M., Shen Y.K. et al. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020;21(6):881–890. https://doi.org/10.1007/s40257-020-00555-7..
DOI: 10.1007/s40257-020-00555-7

Gordon K.B., Blauvelt A., Foley P., Song M., Wasfi Y., Randazzo B. et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018;178(1):132–139. https://doi.org/10.1111/bjd.16008..
DOI: 10.1111/bjd.16008

Langley R.G., Tsai T.F., Flavin S., Song M., Randazzo B., Wasfi Y. et al. Efficacy and safety of guselkumab in patients with psoriasis who have aninadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. https://doi.org/10.1111/bjd.15750..
DOI: 10.1111/bjd.15750

Reich K., Armstrong A.W., Langley R.G., Flavin S., Randazzo B., Li S. et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. https://doi.org/10.1016/S0140-6736(19)31773-8..
DOI: 10.1016/S0140-6736(19)31773-8

Ohtsuki M., Kubo H., Morishima H., Goto R., Zheng R., Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053–1062. https://doi.org/10.1111/1346-8138.14504..
DOI: 10.1111/1346-8138.14504

Ferris L.K., Ott E., Jiang J., Hong H.C., Li S., Han C., Baran W. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatolog Treat. 2020;31(2):152–159. https://doi.org/10.1080/09546634.2019.1587145..
DOI: 10.1080/09546634.2019.1587145

Balak D.M. Fumaric acid esters in the management of psoriasis. Psoriasis (Auckl). 2015;5:9–23. https://doi.org/10.2147/PTT.S51490..
DOI: 10.2147/PTT.S51490

Nast A., Spuls P.I., van der Kraaij G., Gisondi P., Paul C., Ormerod A.D. et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31(12):1951–1963. https://doi.org/10.1111/jdv.14454..
DOI: 10.1111/jdv.14454

Thaçi D., Pinter A., Sebastian M., Termeer C., Sticherling M., Gerdes S. et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2020;183(2):265–275. https://doi.org/10.1111/bjd.18696..
DOI: 10.1111/bjd.18696

Nemoto O., Hirose K., Shibata S., Li K., Kubo H. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study. Br J Dermatol. 2018;178(3):689–696. https://doi.org/10.1111/bjd.16236..
DOI: 10.1111/bjd.16236

Gordon K.B., Duffin K.C., Bissonnette R., Prinz J.C., Wasfi Y., Li S. et al. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015;373(2):136–144. https://doi.org/10.1056/NEJMoa1501646..
DOI: 10.1056/NEJMoa1501646

Zhu Y., Marini J.C., Song M., Randazzo B., Shen Y.K., Li S., Zhou H. Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis. J Invest Dermatol. 2019;139(8):1830–1834.e6. https://doi.org/10.1016/j.jid.2019.02.018..
DOI: 10.1016/j.jid.2019.02.018

Galluzzo M., D’Adamio S., Campione E., Bianchi L., Talamonti M. A safety evaluation of guselkumab for the treatment of psoriasis. Expert Opin Drug Saf. 2018;17(7):741–751. https://doi.org/10.1080/14740338.2018.1488963..
DOI: 10.1080/14740338.2018.1488963

Liu J., Cao S., Kim S., Chung E.Y., Homma Y., Guan X. et al. Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression. Curr Immunol Rev. 2005;1(2):119–137. https://doi.org/10.2174/1573395054065115..
DOI: 10.2174/1573395054065115

Kleinschek M.A., Muller U., Brodie S.J., Stenzel W., Kohler G., Blumenschein W.M. et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol. 2006;176(2):1098–1106. https://doi.org/10.4049/jimmunol.176.2.1098..
DOI: 10.4049/jimmunol.176.2.1098

Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K. et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442(7101):461–465. https://doi.org/10.1038/nature04808..
DOI: 10.1038/nature04808